Edgar Filing: SYNBIOTICS CORP

Prepared by R.R. Donnelley Financial -- Form 10-Q for period ended 6/30/2002

U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT UNDER SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2002

o TRANSITION REPORT UNDER SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 0–11303

SYNBIOTICS CORPORATION
(Exact name of registrant as specified in its charter)

California
(State or other jurisdiction of
incorporation or organization)

95–3737816
(I.R.S. Employer
Identification No.)

11011 Via Frontera
San Diego, California
(Address of principal executive offices)

92127
(Zip Code)

Registrant’s telephone number, including area code: (858) 451-3771

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

As of August 13, 2002, 17,865,279 shares of common stock were outstanding.

SYNBIOTICS CORPORATION

INDEX

			Page

Part I	Item 1.	Financial Statements:

		Condensed Consolidated Balance Sheet - June 30, 2002 and December 31, 2001	1

		Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) - Three and six months ended June 30, 2002 and 2001	2

		Condensed Consolidated Statement of Cash Flows - Six months ended June 30, 2002 and 2001	3

		Notes to Condensed Consolidated Financial Statements	4

	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	10

	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	17

Part II	Item 1.	Legal Proceedings	18

	Item 2.	Changes in Securities and Use of Proceeds	18

	Item 3.	Defaults Upon Senior Securities	18

	Item 4.	Submission of Matters to a Vote of Security Holders	18

	Item 5.	Other Information	18

	Item 6.	Exhibits and Reports on Form 8-K	18

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

Synbiotics Corporation
Condensed Consolidated Balance Sheet

		June 30, 2002			December 31, 2001

		(unaudited)			(audited)
Assets
Current assets:
Cash and equivalents		$	1,733,000		$	1,039,000
Accounts receivable			3,118,000			2,983,000
Inventories			6,044,000			5,059,000
Other current assets			806,000			796,000

			11,701,000			9,877,000
Property and equipment, net			1,504,000			1,648,000
Goodwill			4,275,000			12,074,000
Intangibles, net			2,829,000			2,744,000
Deferred debt issuance costs						7,000
Other assets			144,000			152,000

		$	20,453,000		$	26,502,000

Liabilities and Shareholders Equity:
Current Liabilities:
Accounts payable and accrued expenses		$	5,455,000		$	5,915,000
Current portion of long-term debt			1,325,000			1,200,000
Deferred revenue			150,000			300,000

			6,930,000			7,415,000

Long-term debt			5,307,000			6,032,000
Other liabilities			1,882,000			1,804,000

			7,189,000			7,836,000

Mandatorily redeemable stock			2,604,000			3,107,000

Non-mandatorily redeemable common stock and other shareholders’ equity:
	Common stock, no par value, 24,800,000 shares authorized, 17,865,000 and 8,990,000 shares issued and outstanding at June 30, 2002 and December 31, 2001		46,035,000			40,286,000
Common stock warrants			1,035,000			1,035,000
Accumulated other comprehensive loss			(1,104,000	)		(1,411,000	)
Accumulated deficit			(42,236,000	)		(31,766,000	)

Total non-mandatorily redeemable common stock and other shareholders’ equity			3,730,000			8,144,000

		$	20,453,000		$	26,502,000

See accompanying notes to condensed consolidated financial statements.

-1-

Item 1. Financial Statements (continued)

Synbiotics Corporation
Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) (unaudited)

		Three Months Ended June 30,						Six Months Ended June 30,

			2002			2001			2002			2001

Revenues:
Net sales		$	6,118,000		$	7,195,000		$	12,814,000		$	15,157,000
License fees			75,000			908,000			150,000			969,000
Royalties			2,000			2,000			5,000			4,000

			6,195,000			8,105,000			12,969,000			16,130,000

Operating expenses:
Cost of sales			2,859,000			3,252,000			5,711,000			6,460,000
Research and development			382,000			399,000			792,000			905,000
Selling and marketing			1,292,000			1,492,000			2,768,000			3,056,000
General and administrative			1,103,000			1,596,000			5,889,000			3,192,000

			5,636,000			6,739,000			15,160,000			13,613,000

Income (loss) from operations			559,000			1,366,000			(2,191,000	)		2,517,000
Other income (expense):
Interest, net			(191,000	)		(232,000	)		(358,000	)		(526,000	)

Income (loss) before income taxes			368,000			1,134,000			(2,549,000	)		1,991,000
Provision for income taxes			86,000			23,000			272,000			51,000

Income (loss) before cumulative effect of a change in accounting principle			282,000			1,111,000			(2,821,000	)		1,940,000
Cumulative effect of a change in accounting principle, net of tax									(7,649,000	)

Net income (loss)			282,000			1,111,000			(10,470,000	)		1,940,000
Translation adjustment			452,000			(86,000	)		307,000			(571,000	)

Comprehensive income (loss)		$	734,000		$	1,025,000		$	(10,163,000	)	$	1,369,000

Basic and diluted income (loss) per share:
Income (loss) from continuing operations		$	0.02		$	0.11		$	(0.24	)	$	0.19
	Cumulative effect of a change in accounting principle, net of tax								(0.62	)

Net income (loss)		$	0.02		$	0.11		$	(0.86	)	$	0.19

See accompanying notes to condensed consolidated financial statements.

-2-

Item 1. Financial Statements (continued)

Synbiotics Corporation
Condensed Consolidated Statement of Cash Flows (unaudited)

		Six Months Ended June 30,

			2002			2001

Cash flows from operating activities:
Net (loss) income		$	(10,470,000	)	$	1,940,000
	Adjustments to reconcile net (loss) income to net cash (used for) provided by operating activities:
Depreciation and amortization			558,000			1,149,000
Retention bonus payable in common stock			2,641,000
Cumulative effect of a change in accounting principle			7,817,000
Changes in assets and liabilities (net of acquisitions and dispositions):
Accounts receivable			37,000			(401,000	)
Inventories			(827,000	)		46,000
Deferred taxes						(8,000	)
Other assets			(201,000	)		(120,000	)
Accounts payable and accrued expenses			(773,000	)		(244,000	)
Deferred revenue			(150,000	)		(969,000	)
Other liabilities			74,000			(332,000	)

Net cash (used for) provided by operating activities			(1,294,000	)		1,061,000

Cash flows from investing activities:
Acquisition of property and equipment			(61,000	)		(97,000	)
Proceeds from sale of investment in W3 held for sale						9,000

Net cash used for investing activities			(61,000	)		(88,000	)

Cash flows from financing activities:
Payments of long-term debt			(600,000	)		(600,000	)
Proceeds from issuance of mandatorily redeemable preferred stock, net			2,603,000

Net cash provided by (used for) financing activities			2,003,000			(600,000	)

Net increase in cash and equivalents			648,000			373,000

Effect of exchange rates on cash			46,000			(49,000	)

Cash and equivalents – beginning of period			1,039,000			951,000

Cash and equivalents – end of period		$	1,733,000		$	1,275,000

See accompanying notes to condensed consolidated financial statements.

-3-

Item 1. Financial Statements (continued)

SYNBIOTICS CORPORATION
Notes to Condensed Consolidated Financial Statements (unaudited)

Note 1 – Interim Financial Statements:

The accompanying condensed consolidated balance sheet as of June 30, 2002 and the condensed consolidated statements of operations and comprehensive income (loss) and of cash flows for the three and six months ended June 30, 2002 and 2001 have been prepared by Synbiotics Corporation (the “Company”) and have not been audited. The condensed consolidated financial statements of the Company include the accounts of its wholly-owned subsidiary Synbiotics Europe SAS (“SBIO-E”). All significant intercompany transactions and accounts have been eliminated in consolidation. These financial statements, in the opinion of management, include all adjustments (consisting only of normal recurring accruals) necessary for a fair presentation of the financial position, results of operations and cash flows for all periods presented. The financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K filed for the year ended December 31, 2001. Interim operating results are not necessarily indicative of operating results for the full year.

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Note 2 – New Accounting Pronouncements

As of January 1, 2002, the Company adopted Statement of Financial Accounting Standards No. 142 (“FAS 142”), “Goodwill and Other Intangible Assets”. FAS 142 changed the accounting for goodwill from an amortization method to an impairment-only approach. Under FAS 142, goodwill is tested annually and whenever events or circumstances occur indicating that goodwill might be impaired. Upon adoption of FAS 142, amortization of goodwill recorded for business combinations consummated prior to July 1, 2001 ceased. In connection with the adoption of FAS 142, the Company performed a transitional goodwill impairment assessment. As a result of this impairment assessment, in the first quarter of 2002 the Company recorded an impairment of $7,649,000, net of income tax benefit of $106,000, which is classified as a cumulative effect of a change in accounting principle for the six months ended June 30, 2002. Subsequent impairment assessments will be performed, at a minimum, in the fourth quarter of each year; and subsequent impairments, if any, will be classified as an operating expense. The Company’s measurement of fair value was based upon a “fairness opinion” prepared by an independent investment advisor in conjunction with the Redwood transaction (Note 3).

As of January 1, 2002, the Company adopted Statement of Financial Accounting Standards No. 144 “Accounting for the Impairment or Disposal of Long-Lived Assets” (“FAS 144”). FAS 144 supersedes FAS 121 “Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of”. FAS 144 applies to all long-lived assets (including discontinued operations) and consequently amends Accounting Principles Board Opinion No. 30 (“APB 30”), “Reporting Results of Operations - Reporting the Effects of Disposal of a Segment of a Business”. FAS 144 develops one accounting model for long-lived assets that are to be disposed of by sale. FAS 144 requires that long-lived assets that are to be disposed of by sale be measured at the lower of book value or fair value less cost to sell. Additionally, FAS 144 expands the scope of discontinued operations to include all components of an entity with operations that (1) can be distinguished from the rest of the entity and (2) will be eliminated from the ongoing operations of the entity in a disposal transaction. The adoption of FAS 144 did not have a material impact on the Company’s financial position or results of operations.

Note 3 – Issuance of Preferred Stock and Restructuring of Debt:

In January 2002, the Company designated and authorized 4,000 shares of Series B Preferred Stock (the “Series B Preferred”), and issued 2,800 shares of Series B Preferred to Redwood West Coast, LLC (“Redwood”) in exchange for $2,800,000 cash, less

-4-

Item 1. Financial Statements (continued)

SYNBIOTICS CORPORATION
Notes to Condensed Consolidated Financial Statements (unaudited)

$196,000 of issuance costs. Each Series B Preferred share is entitled to cumulative dividends, payable in cash quarterly, in an annual amount of $75 per share. The Series B Preferred is entitled to a liquidation preference of $1,000 per share, plus accumulated and unpaid dividends. Each share of Series B Preferred has voting power equivalent to 7,785 shares of common stock. Each share of Series B Preferred will become convertible into 7,785 shares of common stock (subject to anti-dilution adjustments) if and when the Company’s Articles of Incorporation are amended to increase the number of authorized shares of common stock to at least 70,000,000. Redwood representatives now constitute a majority of the Company’s Board of Directors, and Redwood also controls approximately 54% of the Company’s voting stock on a fully diluted. The Company agreed to pay an affiliate of Redwood a consulting fee of $15,000 per month beginning in February 2002.

In January 2002, in conjunction with the Redwood transaction, the Company amended cash retention bonus agreements with certain employees (the “Converted Retention Bonuses”) so that, instead of cash, the employees received, on May 15, 2002, an aggregate of 8,254,000 shares of the Company’s common stock under the 1995 Stock Option/Stock Issuance Plan. The Company also agreed to pay the employees’ income tax withholding obligation related to the Converted Retention Bonuses in exchange for the cancellation of options outstanding for an aggregate of 880,000 shares of the Company’s common stock. In January 2002, the Company recorded compensation expense, including the employees’ income tax withholding obligation, related to the Converted Retention Bonuses totalling $3,029,000. In addition, the Company also amended its remaining employee cash retention bonus agreements (the “Cash Retention Bonuses”) so that the amounts that would have become payable upon the consummation of the Redwood transaction will instead be payable in January 2003. The Company recorded compensation expense totalling $653,000 in January 2002 related to the Cash Retention Bonuses. The Cash Retention Bonuses also modified options to purchase an aggregate of 72,000 shares of the Company’s common stock to provide for immediate vesting, upon consummation of the Redwood transaction, and to extend the expiration date to January 25, 2004. No compensation expense was recorded related to these modifications as the exercise prices of all of the options involved was greater than the fair market value of the shares on the modification date.

The Company amended its credit agreement with Comerica Bank — California (“Comerica”) in conjunction with the Redwood transaction. The $7,132,000 principal amount outstanding under the Company’s revolving line of credit and term note, each due in March 2002, was converted into a new $7,132,000 term note. The new note bears interest at the rate of prime plus 2%, and is payable in monthly installments of $100,000 plus accrued interest through January 2003 and monthly installments of $125,000 plus accrued interest thereafter, with all remaining principal due January 25, 2004. In addition, the Company must make a partial prepayment if its EBITDA (earnings before interest, taxes, depreciation and amortization) in 2002 exceeds $4,000,000. As of December 31, 2001, the Company was not in compliance with certain of the original Comerica financial covenants. The amended credit agreement waives all prior instances of non-compliance with financial covenants, and now includes only a minimal financial covenant related to capital expenditures.

Note 4 – Inventories:

Inventories consist of the following:

	June 30, 2002		December 31, 2001

	(unaudited)		(audited)
Inventories:
Raw materials	$	2,918,000	$	2,317,000
Work in process		369,000		318,000
Finished goods		2,757,000		2,424,000

	$	6,044,000	$	5,059,000

-5-

Item 1. Financial Statements (continued)

SYNBIOTICS CORPORATION
Notes to Condensed Consolidated Financial Statements (unaudited)

Note 5 – Goodwill and Other Intangible Assets:

On January 1, 2002, the Company adopted FAS 142 (Note 2). As a result, the Company recorded an impairment loss and ceased to amortize goodwill. The Company has allocated all of its goodwill to its only reporting unit, which is also its only reportable segment (Note 8). Changes in the carrying amount of goodwill were as follows:

Balance at December 31, 2000	$	13,161,000
Additional purchase price for prior acquisitions		277,000
Amortization		(1,445,000	)
Effect of currency exchange rates		81,000

Balance at December 31, 2001		12,074,000
Impairment loss		(7,755,000	)
Effect of currency exchange rates		(44,000	)

Balance at June 30, 2002	$	4,275,000

The reconciliation of reported net income (loss) and net income (loss) per share for the three and six months ended June 30, 2002 and 2001 was as follows:

			Three Months Ended June 30,				Six Months Ended June 30,

			2002		2001		2002			2001

	Reported net income (loss)		$	282,000	$	1,111,000	$	(10,470,000	)	$	1,940,000
	Add: Goodwill amortization					348,000					693,000

.	Adjusted net income (loss)		$	282,000	$	1,459,000	$	(10,470,000	)	$	2,633,000

	Basic and diluted net income (loss) per share:
		Reported net income (loss)	$	0.02	$	0.11	$	(0.86	)	$	0.19
		Add: Goodwill amortization			$	0.04				$	0.07

	Adjusted basic and diluted net income (loss)		$	0.02	$	0.15	$	(0.86	)	$	0.26

Other intangible assets were as follows:

	June 30, 2002				December 31, 2001

	Gross Carrying Value		Accumulated Amortization		Gross Carrying Value		Accumulated Amortization

Patents	$	4,181,000	$	1,605,000	$	3,863,000	$	1,313,000
Licenses		599,000		346,000		512,000		318,000

	$	4,780,000	$	1,951,000	$	4,375,000	$	1,631,000

-6-

Item 1. Financial Statements (continued)

SYNBIOTICS CORPORATION
Notes to Condensed Consolidated Financial Statements (unaudited)

The weighted-average amortization periods for patents and licenses are 9 years and 10 years, respectively, and the weighted-average amortization period for total intangible assets is 9 years. Annual pretax amortization for other intangibles over the next five years is estimated to be as follows:

2003	$	475,000
2004		471,000
2005		438,000
2006		428,000
2007		321,000

	$	2,133,000

Note 6 – Mandatorily Redeemable Stock:

The Series B Preferred (Note 2) defines a merger and/or acquisition as a liquidating event; and as a result, the Series B Preferred is considered to be mandatorily redeemable and is classified outside of permanent shareholders’ equity on the balance sheet.

The 621,000 shares of the Company’s common stock which was issued to Merial SAS (“Merial”) in conjunction with the 1997 acquisition of SBIO-E were subject to a put provision which gave Merial the right, beginning on July 9, 2001, to sell all or any portion of its shares to the Company at a price of $5 per share, for a total of $3,107,000. In June 2001, in conjunction with the assignment to Merial of the Company’s feline leukemia virus (“FeLV”) vaccine distribution rights, Merial waived its rights under the put provision. However, if the Company failed to make certain royalty payments to Merial through April 2002, the rights under the put provision would have reverted to Merial. The Company made the final scheduled payment in April 2002, and reclassified the carrying amount of the common stock from mandatorily redeemable stock to permanent shareholders’ equity as of March 31, 2002.

Note 7 – Income (Loss) per Share:

The following is a reconciliation of net income (loss) and share amounts used in the computations of income (loss) per share:

		Three Months Ended June 30,						Six Months Ended June 30,

		2002			2001			2002			2001

		(unaudited)			(unaudited)			(unaudited)			(unaudited)
Basic and diluted net income (loss) used:
	Income (loss) from continuing operations	$	282,000		$	1,111,000		$	(2,821,000	)	$	1,940,000
	Less cumulative preferred stock dividends		(53,000	)					(90,000	)
	Less accretion of mandatorily redeemable common stock					(46,000	)					(79,000	)

	Income (loss) from continuing operations used in computing basic income (loss) from continuing operations per share		229,000			1,065,000			(2,911,000	)		1,861,000
	Cumulative effect of a change in accounting principle, net of tax								(7,649,000	)

	Net income (loss) used in computingbasic and diluted net income (loss) per share	$	229,000		$	1,065,000		$	(10,560,000	)	$	1,861,000

-7-

Item 1. Financial Statements (continued)

SYNBIOTICS CORPORATION
Notes to Condensed Consolidated Financial Statements (unaudited)

		Three Months Ended June 30,				Six Months Ended June 30,

		2002		2001		2002		2001

		(unaudited)		(unaudited)		(unaudited)		(unaudited)
Shares used:
	Weighted average common shares outstanding used in computing basic income (loss) per share		13,738,000		9,624,000		12,362,000		9,624,000
	Weighted average options and warrants to purchase common stock as determined by the treasury method		341,000		235,000				236,000

	Shares used in computing diluted income (loss) per share		14,079,000		9,859,000		12,362,000		9,860,000

Weighted average options and warrants to purchase common stock as determined by the application of the treasury method totalling 344,000 shares have been excluded from the shares used in computing diluted net income (loss) per share for the six months ended June 30, 2002 as their effect is anti-dilutive. In addition, warrants to purchase 250,000 shares of common stock at $2.00 per share have been excluded from the shares used in computing diluted net income (loss) per share for the three and six months ended June 30, 2002 and 2001, as their exercise price is higher than the weighted average market price for those periods. In addition the effect of the warrants to purchase 250,000 shares of common stock at $2.00 per share was anti-dilutive for the six months ended June 30, 2002.

Note 8 – Segment Information and Significant Customers:

The Company has determined that it has only one reportable segment based on the fact that all of its net sales are from its animal health products. Although the Company sells diagnostic and instrument products, and has sold vaccine products, it does not base its business decision making on a product category basis.

The following are revenues for the Company’s diagnostic, vaccine and instrument products:

	Three Months Ended June 30,				Six Months Ended June 30,

	2002		2001		2002		2001

	(unaudited)		(unaudited)		(unaudited)		(unaudited)
Diagnostics	$	5,720,000	$	6,795,000	$	12,059,000	$	14,082,000
Vaccines				34,000				276,000
Instruments		398,000		366,000		755,000		799,000
Other revenues		77,000		910,000		155,000		973,000

	$	6,195,000	$	8,105,000	$	12,969,000	$	16,130,000

Other revenues for the three months ended June 30, 2001 consist primarily of deferred license fee revenues that were recognized in conjunction with the assignment of a distribution agreement.

-8-

Item 1. Financial Statements (continued)

SYNBIOTICS CORPORATION
Notes to Condensed Consolidated Financial Statements (unaudited)

The following are revenues and long-lived assets information by geographic area:

		Three Months Ended June 30,				Six Months Ended June 30,

		2002		2001		2002		2001

		(unaudited)		(unaudited)		(unaudited)		(unaudited)
Revenues:
	United States	$	4,549,000	$	6,280,000	$	9,214,000	$	11,602,000
	France		464,000		411,000		1,109,000		1,095,000
	Other foreign countries		1,182,000		1,414,000		2,646,000		3,433,000

		$	6,195,000	$	8,105,000	$	12,969,000	$	16,130,000


						June 30,		December 31,
						2002		2001

						(unaudited)		(audited)
Long-lived assets:
	United States					$	6,075,000	$	11,929,000
	France						2,677,000		4,696,000

						$	8,752,000	$	16,625,000

The Company had sales to one customer that totalled 12% and 10% of total revenues for the three and six months ended June 30, 2002, respectively. Sales to one customer totalled 11% and 10% of total revenues for the three and six months ended June 30, 2001, respectively.

Note 9 – Derivative Instruments:

On April 1, 2002, the Company adopted Statement of Financial Accounting Standards No. 133 (“FAS 133”), “Accounting for Derivative Instruments and Hedging Activities,” as amended by Statement of Financial Accounting Standards No. 138, “Accounting for Certain Derivative Instruments and Certain Hedging Activities.” FAS 133, as amended, requires that all derivative instruments be recognized on the balance sheet at fair value. In addition, the standard specifies criteria for designation and effectiveness of hedging relationships and establishes accounting rules for reporting changes in the fair value of a derivative depending on the designated type of hedge. There was no cumulative effect on the Company’s consolidated financials statements of the adoption of FAS 133 as of April 1, 2002 as the Company had no derivative instruments at that time.

The Company is exposed to foreign currency exchange rate fluctuations in the normal course of its business. In June 2002, as part of its risk management strategy, the Company entered into a put option to hedge the foreign currency exposure of its net investment in SBIO-E. The Company’s objective is to offset losses resulting from a decrease in exchange rates below the floor contained in the put option with gains on the derivative instrument. The Company does not enter into any trading or speculative positions with regard to derivative instruments.

If the derivative instrument is effective (i.e., the exchange rates fall below the floor contained in the put option), the change in the fair value of the derivative instrument is recorded in accumulated other comprehensive income (loss) on the balance sheet. If the derivative instrument is ineffective, the change in the fair value of the derivative instrument is recorded in income (loss) from continuing operations on the statement of operations. The Company determines the fair value of the derivative instrument based on quoted market prices, and records the derivative instrument on the balance sheet at fair value. At June 30, 2002, the fair value of the derivative instrument equaled the premium paid for the derivative instrument, and was not material. Accordingly, no amounts related to the derivative instrument were recorded in either accumulated other comprehensive income (loss) or in income (loss) from continuing operations during the three and six months ended June 30, 2002.

-9-

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The information contained in this Management’s Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this Quarterly Report on Form 10-Q contains both historical financial information and forward-looking statements. Forward-looking statements are characterized by words such as “intend”, “plan”, “believe”, “will”, “would”, etc. Historical financial information may not be indicative of future financial performance. In fact, future financial performance may be materially different than the historical financial information presented herein. Moreover, the forward-looking statements about future business or future results of operations are subject to significant uncertainties and risks, including those detailed under the caption “Certain Risk Factors”, which could cause actual future results to differ materially from what is suggested by the forward-looking information.

Results of Operations

Our net sales for the second quarter 2002 decreased by $1,077,000 or 15% from the second quarter of 2001. The decrease reflects a decrease in our diagnostic product sales of $1,075,000 primarily related to canine heartworm diagnostic products. Sales of our diagnostic products decreased due to the loss of one of our larger distributors in January 2002 who accounted for $301,000 of our sales in the second quarter of 2001, $114,000 related to the fourth quarter 2001 transfer of our Japanese diagnostic business to a third party as part of a license agreement, and increased competition in the canine heartworm market. Also, we believe our distributors are carrying less inventory in view of current economic conditions. Our sales of poultry diagnostic products decreased during the second quarter of 2002 due to the June 2001 recall of substantially all of our poultry diagnostic products resulting from manufacturing problems at our supplier, Kirkegaard and Perry Laboratories, Inc. (“KPL”), and a March 2002 recall of certain of our poultry diagnostic products also manufactured by KPL. We believe that the transfer of the manufacturing of these products to our San Diego manufacturing facility, which was completed during the first quarter of 2002, will significantly reduce the likelihood of any future recalls.

Our net sales for the six months ended June 30, 2002 decreased by $2,343,000 or 15% from the six months ended June 30, 2001. The decrease reflects a decrease in our diagnostic product sales of $2,023,000 primarily related to canine heartworm diagnostic products, a decrease in our sales of vaccine products of $242,000, and a decrease in our instrument product sales of $44,000. Sales of our diagnostic products decreased due to the loss of one of our larger distributors in January 2002 who accounted for $881,000 of our sales in the six months ended June 30, 2001, $567,000 related to the fourth quarter 2001 transfer of our Japanese diagnostic business to a third party as part of a license agreement, and increased competition in the canine heartworm market. Also, we believe our distributors are carrying less inventory in view of current economic conditions. Our sales of poultry diagnostic products decreased during the six months ended June 30, 2002 due to the June 2001 recall of substantially all of our poultry diagnostic products resulting from manufacturing problems at KPL, and a March 2002 recall of certain of our poultry diagnostic products also manufactured by KPL. We believe that the transfer of the manufacturing of these products to our San Diego manufacturing facility, which was completed during the first quarter of 2002, will significantly reduce the likelihood of any future recalls. The decrease in our vaccine sales is due solely to our decision on June 1, 2001 to exit the vaccine business. Our instrument product sales decreased primarily due to our 2000 decision to scale back our instrument manufacturing operations, and we expect to dispose of these operations in 2002.

We recognize revenue from product sales when title and risk of loss transfers to our customer, which is generally upon shipment. Amounts we charge to our customers for shipping and handling are included in our net sales. We provide promotional discounts and rebates to certain of our distributors. Based upon the structure of these rebate programs and our past history, we are able to accurately estimate the amount of rebates at the time of sale. These rebates are recorded as a reduction of our net sales. We recognize license fee revenue ratably over the license term when we have further performance obligations to our licensee. In the event that we have no further performance obligations to our licensee, we recognize license fee revenue upon receipt.

Our cost of sales as a percentage of our net sales was 47% during the second quarter of 2002 compared to 45% during the second quarter of 2001, and was 45% during the six months ended June 30, 2002 compared to 43% during the six months ended June 30, 2001. The lower gross margins are a direct result of the decrease in our sales during the three and six months ended June 30, 2002, and the fact that a significant portion of our manufacturing costs are fixed.

Among our major products, our DiroCHEK^® canine heartworm diagnostic products are manufactured at our facilities, whereas our WITNESS^® canine heartworm and feline leukemia diagnostic products, VetRED^® and the SCA 2000™ products are manufactured by third parties. Our poultry diagnostic products were manufactured for us by a third party during 2001. In addition to affecting our gross margins, outsourcing of manufacturing renders us relatively more dependent on the third-party manufacturers.

-10-

We completed the transfer of the manufacturing of our poultry diagnostic products from our supplier to our manufacturing facilities in San Diego during the first quarter of 2002, although some of the products are awaiting licensure by the USDA. We believe that our gross margins on these products will improve as we will have more products to absorb our fixed manufacturing costs.

Our research and development expenses decreased by $17,000 or 4% during the second quarter of 2002 as compared to the second quarter of 2001, and decreased by $113,000 or 12% during the six months ended June 30, 2002 as compared to the six months ended June 30, 2001. The decreases are due primarily to the decrease in research activities performed for us by third parties, and decreases in patent legal expense. Our research and development expenses as a percentage of our net sales were 6% during the three and six months ended June 30, 2002 and 2001.

Our selling and marketing expenses decreased by $200,000 or 13% during the second quarter of 2002 as compared to the second quarter of 2001, and decreased by $288,000 or 9% during the six months ended June 30, 2002 as compared to the six months ended June 30, 2001. The decreases are due to a concerted effort to reduce selling and marketing expenses. Our selling and marketing expenses as a percentage of our net sales were 21% during the second quarter of 2002 and 2001, and were 22% and 20% during the six months ended June 30, 2002 and 2001, respectively.

Our general and administrative expenses decreased by $493,000 or 31% during the second quarter of 2002 as compared to the second quarter of 2001, due primarily to the fact that goodwill is no longer amortized. Our general and administrative expenses increased by $2,697,000 or 84% during the six months ended June 30, 2002 as compared to the six months ended June 30, 2001. The increase is primarily due to $3,682,000 of retention bonuses that became payable upon the consummation of the January 2002 Redwood Series B preferred stock investment transaction, offset by the fact that goodwill is no longer amortized. Our general and administrative expenses as a percentage of our net sales were 18% and 22% during the second quarter of 2002 and 2001, respectively, and were 46% and 21% during the six months ended June 30, 2002 and 2001, respectively. Excluding the first quarter 2002 bonus expense and the goodwill amortization during the three and six months ended June 30, 2001, our general and administrative expenses would have been $1,103,000 and $1,248,000 during the second quarter of 2002 and 2001, respectively, and $2,207,000 and $2,499,000 during the six months ended June 30, 2002 and 2001, respectively, or 18% and 17% of our net sales during the second quarter of 2002 and 2001, respectively, and 17% and 16% of our net sales during the six months ended June 30, 2002 and 2001, respectively.

Our net interest expense decreased by $41,000 or 18% during the second quarter of 2002 as compared to the second quarter of 2001, and decreased by $168,000 or 32% during the six months ended June 30, 2002 as compared to the six months ended June 30, 2001. The decreases are due to decreases in the prime rate during 2001, and decreases in the outstanding principal balance.

We recognized a provision for income taxes of $272,000 during the six months ended June 30, 2002 as compared to a provision for income taxes of $51,000 during the six months ended June 30, 2001. The change is primarily due to permanent differences between income for financial reporting purposes and tax reporting purposes in 2002 related to the retention bonus. In addition, the change in our ownership resulting from the January 2002 Redwood transaction limits the utilization of both Federal and state net operating loss carryforwards to $59,000 per year. As a result of this limitation, $15,999,000 of our Federal net operating loss carryforwards, and $1,266,000 of our state net operating loss carryforwards, may expire before they can be utilized.

Cash was extremely tight for us throughout 2001 and into the first quarter of 2002, and at times we were on credit hold with several of our key suppliers. Our lack of liquidity may have had a detrimental impact on our business in 2001 and into the first six months of 2002. It is unclear whether any impact on our business would continue into the last two quarters of 2002.

As of January 1, 2002, we adopted Statement of Financial Accounting Standards No. 142 (“FAS 142”), “Goodwill and Other Intangible Assets”. FAS 142 changed the accounting for goodwill from an amortization method to an impairment-only approach. Under FAS 142, goodwill is tested annually and whenever events or circumstances occur indicating that goodwill might be impaired. Upon adoption of FAS 142, amortization of goodwill recorded for business combinations consummated prior to July 1, 2001 ceased. In connection with the adoption of FAS 142, we performed a transitional goodwill impairment assessment. As a result of this impairment assessment, we recorded an impairment of $7,649,000, net of income tax benefit of $106,000, which is classified as a cumulative effect of a change in accounting principle in the first quarter of 2002. We will perform subsequent impairment assessments, at a minimum, in the fourth quarter of each year; and subsequent impairments, if any, will be classified as an operating expense. Our measurement of fair value was based upon a “fairness opinion” prepared by an independent investment advisor in conjunction with the Redwood transaction.

-11-

As of January 1, 2002, we adopted Statement of Accounting Standards No. 144 “Accounting for the Impairment or Disposal of Long-Lived Assets” (“FAS 144”). FAS 144 supersedes FAS 121 “Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of”. FAS 144 applies to all long-lived assets (including discontinued operations) and consequently amends Accounting Principles Board Opinion No. 30 (“APB 30”), “Reporting Results of Operations - Reporting the Effects of Disposal of a Segment of a Business”. FAS 144 develops one accounting model for long-lived assets that are to be disposed of by sale. FAS 144 requires that long-lived assets that are to be disposed of by sale be measured at the lower of book value or fair value less cost to sell. Additionally, FAS 144 expands the scope of discontinued operations to include all components of an entity with operations that (1) can be distinguished from the rest of the entity and (2) will be eliminated from the ongoing operations of the entity in a disposal transaction. The adoption of FAS 144 did not have a material impact on the our financial position or results of operations.

Financial Condition and Liquidity

In January 2002, we issued 2,800 shares of Series B preferred stock to Redwood West Coast, LLC (“Redwood”), in exchange for $2,800,000 cash. Without this investment, we would not have had the working capital necessary to continue our business. The Series B preferred shares may become convertible into an aggregate of 21,797,000 shares of our common stock, are entitled to quarterly cumulative dividends at a 7.5% annual rate and are entitled to an aggregate liquidation preference of $2,800,000 plus accumulated and unpaid dividends. The Series B preferred stock defines a merger and/or acquisition as a liquidating event; and as a result, the Series B preferred stock is considered to be mandatorily redeemable and is classified outside of permanent shareholders’ equity on the balance sheet. Redwood representatives now constitute a majority of our board of directors, and Redwood also controls approximately 54% of our voting stock on a fully diluted basis.

In conjunction with the Redwood transaction, and pursuant to selectively amended retention bonus agreements, we issued, on May 15, 2002, an aggregate of 8,254,000 shares of our common stock to certain employees. We also agreed to pay the employees’ income tax withholding obligation related to the stock retention bonuses in exchange for the cancellation of options outstanding for an aggregate of 880,000 shares of our common stock. In addition, we also amended cash retention bonus agreements with certain of our employees so that $653,000 that would have become payable upon the consummation of the Redwood transaction will instead be payable in January 2003. In addition, under the employees’ cash retention bonus agreements, options to purchase an aggregate of 72,000 shares of our common stock became immediately vested upon consummation of the Redwood transaction, and the expiration date of the 72,000 stock option was extended to January 25, 2004. We recorded compensation expense in the first quarter of 2002 totalling $3,682,000 related to the retention bonuses.

We amended our credit agreement with Comerica Bank – California (“Comerica”) in conjunction with the Redwood transaction. Without the amendment, we could not have repaid our indebtedness to Comerica when it came due. The $7,132,000 principal amount outstanding under our revolving line of credit and term note, each due in March 2002, was converted into a new $7,132,000 term note. The new note bears interest at the rate of prime plus 2%, and is payable in monthly installments of $100,000 plus accrued interest through January 2003 and monthly installments of $125,000 plus accrued interest thereafter, with all remaining principal due January 25, 2004. In addition, we must make a partial prepayment if our EBITDA (earnings before interest, taxes, depreciation and amortization) in 2002 exceeds $4,000,000. As of December 31, 2001, we were not in compliance with certain of the original Comerica financial covenants. The amended credit agreement waived all prior instances of non-compliance with financial covenants, and includes only minimal financial covenants for the future. We believe we will be able to repay or refinance the amended Comerica note when it comes due in 2004.

The following table summarizes the future cash payments related to our contractual obligations as of June 30, 2002 (amounts are in thousands):

	Total		2002		2003		2004		2005		2006		Thereafter

Long-term debt	$	6,632	$	600	$	1,475	$	4,557
Operating leases		4,436		447		584		527	$	536	$	368	$	1,974
Other long-term obligations		2,500								1,000		1,500

-12-

We believe that our present capital resources, including our working capital of $4,771,000 at June 30, 2002, as well as our anticipated cash from operations, are sufficient to meet our working capital needs and meet our contractual obligations for at least the next twelve months.

The 621,000 shares of our common stock which we issued to Merial in conjunction with the 1997 acquisition of Synbiotics Europe SAS (“SBIO-E”) were subject to a put provision which gave Merial the right, beginning on July 9, 2001, to sell all or any portion of its shares to us at a price of $5 per share, for a total of $3,107,000. In June 2001, in conjunction with the assignment to Merial of our FeLV vaccine distribution rights, Merial waived its rights under the put provision. However, if we failed to make certain royalty payments to Merial through April 2002, the rights under the put provision would have reverted to Merial. We made the final scheduled payment in April 2002, and reclassified the carrying amount of the stock from mandatorily redeemable stock to permanent shareholders’ equity as of March 31, 2002.

Our operations are seasonal due to the sales of our canine heartworm diagnostic products. Our sales and profits tend to be concentrated in the first half of the year, as our distributors prepare for the heartworm season by purchasing diagnostic products for resale to veterinarians. The operations of SBIO-E have reduced our seasonality as sales of their large animal diagnostic products tend to occur evenly throughout the year. We believe that increased sales of our SCA 2000 instruments and supplies and our poultry diagnostic products will also reduce our seasonality.

Certain Risk Factors

Our future operating results are subject to a number of factors, including:

We may need additional capital in the future

We currently anticipate that our existing cash balances and cash flow expected to be generated from future operations will be sufficient to meet our liquidity needs for at least the next twelve months. However, we may need to raise additional funds if our estimates of revenues, working capital and/or capital expenditure requirements change or prove inaccurate or in order for us to respond to unforeseen technological or marketing hurdles or to take advantage of unanticipated opportunities.

Further, our future capital requirements will depend on many factors beyond our control or ability to accurately estimate, including continued scientific progress in our product development programs, the cost of manufacturing scale-up, the costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims, the cost involved in patent infringement litigation, competing technological and market developments, and the cost of establishing effective sales and marketing arrangements. In addition, we expect to review potential acquisitions that would complement our existing product offerings or enhance our technical capabilities. While we have no current agreements with respect to any such acquisition, any future transaction of this nature could require potentially significant amounts of capital. Such funds may not be available at the time or times needed, or available on terms acceptable to us. If adequate funds are not available, or are not available on acceptable terms, we may not be able to take advantage of market opportunities, to develop new products, or to otherwise respond to competitive pressures. This inability could materially harm our business.

The market in which we operate is intensely competitive, even with regard to our key canine heartworm diagnostic products, and many of our competitors are larger and more established

The market for animal health care products is extremely competitive. Companies in the animal health care market compete to develop new products, to market and manufacture products efficiently, to implement effective research strategies, and to obtain regulatory approval. Our current competitors include IDEXX Laboratories, a significantly larger company, and Heska Corporation. These companies have greater financial, manufacturing, marketing, and research resources than we do. In addition, IDEXX Laboratories prohibits its distributors from selling competitors’ products, including ours. Further, additional competition could come from new entrants to the animal health care market. We cannot assure you that we will be able to compete successfully in the future or that competition will not harm our business.

Our canine heartworm diagnostic products constituted 43% of our sales for the six months ended June 30, 2002. In addition to our historic competition with IDEXX Laboratories, the sales leader in this product category, our sales were substantially affected

-13-

in 1999 - 2002 by a new heartworm product from Heska. We are suing Heska, claiming that its heartworm product infringes our patent.

We have a history of losses and an accumulated deficit

We did not achieve profitability for the years ended December 31, 2001 and 2000, and we have had a history of annual losses. We have incurred a consolidated accumulated deficit of $42,236,000 at June 30, 2002. We may not achieve annual profitability again and if we are profitable in the future there can be no assurance that profitability can be sustained.

We rely on third party distributors for a substantial portion of our sales

We have historically depended upon distributors for a large portion of our sales, and we may not have the ability to establish and maintain an adequate independent sales and marketing capability in any or all of our targeted markets. Distributor agreements render our sales exposed to the efforts of third parties who are not employees of Synbiotics and over whom we have no control. Their failure to generate significant sales of our products could materially harm our business. Reduction by these distributors of the quantity of our products which they distribute would materially harm our business. In addition, IDEXX Laboratories’ prohibition against its distributors carrying competitors’ products, including ours, has made, and could continue to make, some distributors unavailable to us.

The effects of our 2001 liquidity issue may linger

There is no assurance that acquired businesses can be successfully combined

There can be no assurance that the anticipated benefits of the April 2000 acquisition of the poultry product line from Kirkegaard & Perry Laboratories, Inc. (“KPL”), or any other future acquisitions (collectively, the “Acquired Business”) will be realized. Acquisitions of businesses involve numerous risks, including difficulties in the assimilation of the operations, technologies and products of the Acquired Business, introduction of different distribution channels, potentially dilutive issuances of equity and/or increases in leverage and risk resulting from issuances of debt securities, the need to establish internally operating functions which had been previously provided pre-acquisition by a corporate parent, accounting charges, operating companies in different geographic locations with different cultures, the potential loss of key employees of the Acquired Business, the diversion of management’s attention from other business concerns and the risks of entering markets in which we have no or limited direct prior experience. In addition, there can be no assurance that the acquisitions will not have a material adverse effect upon our business, results of operations, financial condition or cash flows, particularly in the quarters immediately following the consummation of the acquisition, due to operational disruptions, unexpected expenses and accounting charges which may be associated with the integration of the Acquired Business and us, as well as operating and development expenses inherent in the Acquired Business itself as opposed to integration of the Acquired Business. We did not achieve the hoped-for benefits from some of our past acquisitions, most notably W3COMMERCE (2000).

We depend on key executives and personnel

Our future success will depend, to a significant extent, on the ability of our management to operate effectively, both individually and as a group. Competition for qualified personnel in the animal health care products industry is intense, and we may not be successful in attracting and retaining such personnel. There are only a limited number of persons with the requisite skills to serve in those positions and it may become increasingly difficult to hire such persons. The loss of the services of any of our key personnel or the inability to attract or retain qualified personnel could harm our business.

We depend on third party manufacturers

We contract for the manufacture of some of our products, including our Witness^® canine heartworm and feline leukemia diagnostic products, VetRED^®, some of our poultry diagnostic products and our SCA 2000™ products. We also expect that

-14-

some of our anticipated new products will be manufactured by third parties. In addition, some of the products manufactured for us by third parties, including Witness^® canine heartworm and feline leukemia diagnostic products and VetRED^®, are licensed to us by their manufacturers. There are a number of risks associated with our dependence on third-party manufacturers including:

	•	reduced control over delivery schedules;

	•	quality assurance;

	•	manufacturing yields and costs;

	•	the potential lack of adequate capacity during periods of excess demand;

	•	limited warranties on products supplied to us;

	•	increases in prices and the potential misappropriation of our intellectual property; and

	•	limited negotiating leverage in the event of disputes with the third-party manufacturers.

If our third party manufacturers fail to supply us with an adequate number of finished products, our business would be significantly harmed. We have no long-term contracts or arrangements with any of our vendors that guarantee product availability, the continuation of particular payment terms or the extension of credit limits.

If we encounter delays or difficulties in our relationships with our manufacturers, the resulting problems could have a material adverse effect on us.

In June 2001, KPL instituted a recall of substantially all of our poultry diagnostic products that were manufactured by KPL due to a defective conjugate contained in the products. We replaced the affected products that were held by our customers. The cost of this recall and the related replacement products was borne by KPL. However, our sales of poultry diagnostic products since then have been materially adversely affected, and our future sales of these products could be materially adversely affected. In the first quarter of 2002, KPL instituted another recall of certain of our poultry diagnostic products that were manufactured by KPL due to a contaminated positive control contained in the products. We believe that the transfer of the manufacturing of these products to our San Diego manufacturing facility, which was completed during the first quarter of 2002, will significantly reduce the likelihood of any future recalls.

We rely on new and recent products

We rely to a significant extent on new and recently developed products, and expect that we will need to continue to introduce new products to be successful in the future. There can be no assurance that we will obtain and maintain market acceptance of our products. There can be no assurance that future products will meet applicable regulatory standards, be capable of being produced in commercial quantities at acceptable cost or be successfully commercialized.

There can be no assurance that new products can be manufactured at a cost or in quantities necessary to make them commercially viable. If we are unable to produce internally, or to contract for, a sufficient supply of our new products on acceptable terms, or if we should encounter delays or difficulties in our relationships with manufacturers, the introduction of new products would be delayed, which could have a material adverse effect on our business.

Our canine heartworm business is seasonal

Our operations are seasonal due to the timing of sales of our canine heartworm diagnostic products. Our sales and profits tend to be concentrated in the first half of the year as our distributors prepare for the heartworm season by purchasing diagnostic products for resale to veterinarians. One effect of this is a need to devote large amounts of cash to building canine heartworm diagnostic products inventory in preparation for the canine heartworm selling season at a time when our working capital is relatively low.

-15-

Any failure to adequately establish or protect our proprietary rights may adversely affect us

We rely on a combination of patent, copyright, and trademark laws, trade secrets, and confidentiality and other contractual provisions to protect our proprietary rights. These measures afford only limited protection. We currently have 13 issued U.S. patents and one pending patent application. Our means of protecting our proprietary rights in the U.S. or abroad may not be adequate and competitors may independently develop similar technologies. Our future success will depend in part on our ability to protect our proprietary rights and the technologies used in our principal products. Despite our efforts to protect our proprietary rights, unauthorized parties may attempt to copy aspects of our products or to obtain and use trade secrets or other information that we regard as proprietary. In addition, the laws of some foreign countries do not protect our proprietary rights as fully as do the laws of the United States. Issued patents may not preserve our proprietary position. Even if they do, competitors or others may develop technologies similar to or superior to our own. If we do not enforce and protect our intellectual property, our business will be harmed. From time to time, third parties, including our competitors, have asserted patent, copyright, and other intellectual property rights to technologies that are important to us. We expect that we will increasingly be subject to infringement claims as the number of products and competitors in the animal health care market increases.

The results of any litigated matter are inherently uncertain. In the event of an adverse result in any litigation with third parties that could arise in the future, we could be required to:

	•	pay substantial damages, including treble damages if we are held to have willfully infringed;

	•	cease the manufacture, use and sale of infringing products;

	•	expend significant resources to develop non-infringing technology; or

	•	obtain licenses to the infringing technology.

Licenses may not be available from any third party that asserts intellectual property claims against us on commercially reasonable terms, or at all.

Also, litigation is costly regardless of its outcome and can require significant management attention. For example, in 1997, Barnes-Jewish Hospital filed an action against us claiming that our canine heartworm diagnostic products infringe their patent. We settled this lawsuit, but there can be no assurance that we would be able to resolve similar incidents in the future. Our patent infringement litigation against Heska’s use of heartworm diagnostic technology is also expensive.

Also, because our patents and patent applications cover novel diagnostic approaches,:

	•	the patent coverage which we receive could be significantly narrower than the patent coverage we seek in our patent applications; and

	•	our patent positions involve complex legal and factual issues which can be hard for patent examiners or lawyers asserting patent coverage to successfully resolve.

Because of this, our patent position could be vulnerable and our business could be materially harmed.

The U.S. patent application system also exposes us to risks. In the United States, the first party to make a discovery is granted the right to patent it and patent applications are generally maintained in secrecy for 18 months. For these reasons, we can never know if we are the first to discover particular technologies. Therefore, we can never be certain that our technologies will be patented and we could become involved in lengthy, expensive, and distracting disputes concerning whether we were the first to make the disputed discovery. Any of these events would materially harm our business.

Our business is regulated by the United States and various foreign governments

Our business is subject to substantial regulation by the United States government, most notably the United States Department of Agriculture, and the French government. In addition, our operations may be subject to future legislation and/or rules issued by

-16-

domestic or foreign governmental agencies with regulatory authority relating to our business. There can be no assurance that we will continue to be in compliance with any of these regulations.

For marketing outside the United States, we and our suppliers are subject to foreign regulatory requirements, which vary widely from country to country. There can be no assurance that we and our suppliers will meet and sustain compliance with any such requirements.

We use hazardous materials

Our business requires that we store and use hazardous materials and chemicals. Although we believe that our procedures for storing, handling, and disposing of these materials comply with the standards prescribed by local, state, and federal regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated. If any of these materials were mishandled, or if an accident with them occurred, the consequences could be extremely damaging and we could be held liable for them. Our liability for such an event would materially harm our business and could exceed all of our available resources for satisfying it.

Item 3 – Quantitative and Qualitative Disclosures About Market Risk

Our market risk consists primarily of the potential for changes in interest rates and foreign currency exchange rates.

Interest Rate Risk

The fair value of our debt at June 30, 2002 was $6,632,000, which has a variable interest rate based on the prime rate. We do not hedge our interest rate risk, nor do we hold any trading or speculative positions with regard to derivative instruments based on interest rates.

A change in interest rates of five percentage points would have a material impact on our financial condition, results of operations and cash flows as it relates to our variable rate debt. In addition, if interest rates increased by five percentage points our ability to refinance our bank debt would be seriously compromised.

Foreign Currency Exchange Rate Risk

Our foreign currency exchange rate risk relates to the operations of SBIO-E as it transacts business in Euros, its local currency. However, this risk is limited to our intercompany receivable from SBIO-E and the conversion of its financial statements into the U.S. dollar for consolidation. There is no foreign currency exchange rate risk related to SBIO-E’s transactions outside of the European Union as those transactions are denominated in Euros. Similarly, all of the foreign transactions of our U.S. operations are denominated in U.S. dollars. We do not hedge our cash flows on intercompany transactions, nor do we hold any trading or speculative positions with regard to derivative instruments based on currency exchange rates.

In June 2002, as part of our risk management strategy, we entered into a put option to hedge the foreign currency exposure of our net investment in SBIO-E. Our objective is to offset losses resulting from a decrease in exchange rates below the floor contained in the put option with gains on the derivative instrument. If the derivative instrument is effective (i.e., the exchange rates fall below the floor contained in the put option), the change in the fair value of the derivative instrument is recorded in accumulated other comprehensive income (loss) on the balance sheet. If the derivative instrument is ineffective, the change in the fair value of the derivative instrument is recorded in income (loss) from continuing operations on the statement of operations. We determine the fair value of the derivative instrument based on quoted market prices, and record the derivative instrument on the balance sheet at fair value. At June 30, 2002, the fair value of the derivative instrument equaled the premium paid for the derivative instrument, and was not material. Accordingly, no amounts related to the derivative instrument were recorded in either accumulated other comprehensive income (loss) or in income (loss) from continuing operations during the three and six months ended June 30, 2002.

-17-

As a result, the effects of a 5% change in exchange rates would have a material impact on our financial condition, results of operations and cash flows, but only to the extent that it relates to the conversion of SBIO-E’s financial statements, including its intercompany payable, into the U.S. dollar for consolidation.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

No material changes.

Item 2. Changes in Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

On the date of filing this report, a cumulative dividend arrearage of $108,000 existed on our Series B preferred Stock.

Item 4. Submission of Matters to a Vote of Security Holders

None.

Item 5. Other Information

None.

Item 6. Exhibits and Reports on Form 8-K

(a)	Exhibits

	99.1	Certification Under Section 906 of the Sarbanes-Oxley Act of 2002.

(b)	Reports on Form 8-K

	On April 30, 2002, we filed a Form 8-K announcing the dismissal of PricewaterhouseCoopers LLP as our independent auditors, and the appointment of Levitz, Zacks & Ciceric as our independent auditors.

-18-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SYNBIOTICS CORPORATION

Date: August 13, 2002	/s/ Michael K. Green


	Michael K. Green
	Senior Vice President and Chief Financial Officer
	(signing both as a duly authorized officer and as principal financial officer)

-19-

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.

EXHIBITS

FORM 10-Q

UNDER

SECURITIES EXCHANGE ACT OF 1934

SYNBIOTICS CORPORATION

Exhibit Index

Exhibit No.		Exhibit

99.1		Certification Under Section 906 of the Sarbanes-Oxley Act of 2002.